Authors

S Das¹; 
¹ AstraZeneca, UK

Discussion

Genomic analysis using 455,000 UK Biobank exome sequences to identify candidate drug targets S.Das1, K. Mégy1, A. O’Neill1, G. Alamgir1, J. Harrow1, O. Burren1, Q. Wang2, K. Carss1, E. Wheeler1, R. S. Dhindsa2, A. Harper1, A. Nag1, I. Tachmazidou1, D. Vitsios1, S. Deevi1, S. Wasilewski1, K. R. Smith1, S. Petrovski1, AstraZeneca Genomics Initiative. 1) Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. 2) Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA. Incorporating human genomic data into the assessment of drug targets at an early stage has been shown to significantly increase drug pipeline success rates[1],[2]. AstraZeneca established the Centre for Genomics Research to implement an ambitious Genomics Initiative, with the following goals: 1) attain a better understanding of disease biology, 2) identify and validate novel drug target candidates, 3) explore patient stratification and precision medicine strategies, and 4) deliver insights into drug repositioning and safety